Leading Computational Biologist Eran Segal Joins XBiome's Scientific Advisory Board

Shenzhen Xbiome Biotechnology Co., Ltd., a clinical-stage AI-driven microbiome research and industrial translation platform, announced today that renowned computational and systems biologist Professor Eran Segal of the Weizmann Institute of Science has officially joined its Scientific Advisory Board (SAB).

As one of the world’s most distinguished “benchmark” scientists in the field of microbiology, Professor Segal will join academic and industry leaders on the Scientific Advisory Board to provide valuable scientific insights for refining XBiome’s data-driven drug discovery platform. Additionally, drawing on his successful experience with personalized nutrition programs at the Weizmann Institute of Science, he will offer strategic guidance for XBiome’s upcoming expansion into precision nutrition services based on its AI+BT platform.

Professor Eran Segal

“We warmly welcome Professor Siegel to join the Global Scientific Advisory Board,” stated Dr. Tan Yan, Co-founder and CEO of Xbiome. “Professor Siegel boasts an outstanding track record and profound insights across multiple fields, including microbiome research and precision nutrition. His appointment underscores that Xbiome’s AI+BT technology platform has gained recognition from top-tier scientists worldwide; it also demonstrates Xbiome’s commitment to accelerating its international R&D layout and expanding its presence in precision nutrition. We are confident that Professor Siegel will help Xbiome build world-class capabilities and a technological platform for in silico microbiome research.”

Professor Siegel boasts over 20 years of experience in fundamental research in molecular biology and computational biology. He has achieved remarkable success and wields significant influence in fields such as data-driven precision medication and precision nutrition for longevity extension. Over the years, he has published nearly 200 academic papers, including approximately 20 in Nature Cell Biology (Impact Factor: 28.213), establishing him as one of the most distinguished global leaders in his discipline. In recent years, Professor Siegel has also served as a medical advisor to the Israeli Cabinet, conducting epidemiological research on COVID-19 and making substantial contributions to combating the global pandemic.

Professor Eran Segal teaches at the Weizmann Institute of Science.

Professor Segal is a Professor at the Faculty of Mathematics and Computer Science, Weizmann Institute of Science, Israel. He leads the Segal Lab, an interdisciplinary laboratory comprising computational biologists, experts in computational and systems biology, and experimental scientists. With extensive expertise in machine learning, computational biology, and the analysis of heterogeneous high-throughput genomic data, his research focuses on microbiomics, nutrition, and genetics, as well as their impacts on health and disease. His research aim is to advance precision medicine/personalized medicine by leveraging big data from human populations.

Led by Professor Segal and other scientists, the Weizmann Institute of Science launched the Personalized Nutrition Project, a large-scale nutritional science study aimed at helping individuals make dietary choices that promote health and enhance quality of life. It is the world’s first personalized nutrition study to combine extensive data collection with precise predictive algorithms. Professor Segal employed a self-developed machine learning algorithm that integrates data on gut microbiota, blood biomarkers, health questionnaires, anthropometric measurements, and food logs to accurately predict volunteers’ blood glucose levels and provide personalized nutritional guidance, with gut microbiota data proving particularly informative. The project achieved remarkable success, and its findings were published in the journal Cell.

Professor Siegel earned his Bachelor’s degrees in Computer Science and Economics from Tel Aviv University in 1998. In 2004, under the supervision of renowned computational scientist Daphne Koller, he received a Fulbright Scholarship and obtained his Ph.D. in Computational Science from Stanford University. In 2007, he was awarded the Overton Prize by the International Society for Computational Biology. In 2011, he was appointed as a Professor at the Weizmann Institute of Science.

Shenzhen XBiome Biotechnology Co., Ltd., founded in 2017, possesses a leading AI-driven microbiome research and industrial translation platform, with strategic layouts centered on three key areas: Fecal Microbiota Transplantation (FMT), drug discovery, and probiotics. In the field of drug discovery, the team has established a presence in oncology, digestive diseases, immune-related disorders, and urological diseases, with four drug candidates currently in clinical stages. Regarding FMT, XBiome has collaborated with nearly 20 renowned tertiary Grade-A hospitals in China, including Peking University Cancer Hospital and Peking Union Medical College Hospital of the Chinese Academy of Medical Sciences, to conduct clinical research on gut microbiota across various indications. Additionally, the company has developed an AI-FMT personalized precision gut microbiota therapy project, targeting the broader health market to benefit individuals with chronic diseases and sub-health conditions. In the probiotics sector, XBiome has completed commercial collaborations and technology transfers with several leading domestic and international health companies, while continuously advancing the development of proprietary bacterial strains.